Brief: Pharmather Announces Submission Of IND Application With FDA For Phase 2 Clinical Trial Evaluating Ketamine In Treatment Of Parkinson’s Disease
20/04/2021 12:03
April 20 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER ANNOUNCES SUBMISSION OF IND APPLICATION WITH
THE FDA
FOR PHASE 2 CLINICAL TRIAL EVALUATING KETAMINE IN THE TREATMENT
OF PARKINSON’S DISEASE
Source text for Eikon: ID:nGNX2G6t6m
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application